Trastuzumab deruxtecan – July 2023

• Brand names:
  • Enhertu®
• Pharmaceutical Company:
  • AstraZeneca Pty Ltd
• Condition/Indication: Human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (mBC)
• Meeting Date: July 2023
• Public Summary Document (PSD) July 2022 December 2022 March 2023 July 2023 PBAC Meetings - (PDF 2MB)
• Public Summary Document (PSD) July 2022 December 2022 March 2023 July 2023 PBAC Meetings - (Word 1.4MB)

Related Public Summary Documents

• Trastuzumab deruxtecan – July 2022
• Trastuzumab deruxtecan – December 2022
• Trastuzumab deruxtecan – March 2023